Discover Emergent BioSolutions' Q1 2025 progress: revenue growth, improved liquidity, NARCAN updates, and strategic outlook.

Merck is not alone, with a number of companies making deals to leverage the growing pipeline of therapeutic candidates developed in China, such as Bavarian Nordic’s agreement to progress a ...

Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line therapies due to clinicians’ unfamiliarity with treatment guidelines and misinformation about ...

For Q1 2025, cost of product and services sales, net decreased $56.1 million, or 39%, as compared with Q1 2024. The decrease was driven by decreases in cost of Commercial Product sales of $27.6 ...